Pharmacogenetics of cardiovascular drugs

Briefings in Functional Genomics and Proteomics

Volumn 1, Issue 1, 2002, Pages 66-79

  Johnson, Julie A ^a,b   Humma, Larisa M ^c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Drug metabolism; Drug response; Drug targets; Genetic polymorphisms; Pharmacogenetics; Pharmacogenomics

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CARDIOVASCULAR AGENT; CYTOCHROME P450; GLYCOPROTEIN P;

CLINICAL TRIAL; GENETICS; HUMAN; METABOLISM; PHARMACOGENETICS; PHYSIOLOGY; REVIEW;

ARYLAMINE N-ACETYLTRANSFERASE; CARDIOVASCULAR AGENTS; CLINICAL TRIALS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; P-GLYCOPROTEIN; PHARMACOGENETICS;

EID: 0345924181     PISSN: 14739550     EISSN: 14774062     Source Type: Journal    
DOI: 10.1093/bfgp/1.1.66     Document Type: Article

References (97)

1. Roses, A. D. (2000), 'Pharmacogenetics and the practice of medicine', Nature, Vol, 405, pp. 857-865. (Pubitemid 30407864)
2. Evans, W. E. and Johnson, J. A. (2001), 'Pharmacogenomics: the inherited basis for inter-individual variability in drug response'. Ann. Rev. Genomics Hum. Genet., Vol. 2, pp. 9-39. (Pubitemid 35264999)
3. Evans, W. E. and Relling, M. V. (1999), 'Pharmacogenomics: translating functional genomics into rational therapeutics', Science, Vol. 286, pp. 487-491.
4. Heart Failure Society of America (HFSA) practice guidelines (1999), 'HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - pharmacological approaches', J. Card. Fail., Vol. 5, pp. 357-382.
5. Materson, B.J., Reda, D.J. and Cushman, W. C. (1995), 'Department of Veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents', Am. J. Hypertens., Vol. 8, pp. 189-192.
6. Exner, D. V., Domanski, M.J. and Cohn, J. N. (2001), 'Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction', N. Engl. J. Med., Vol. 344, pp. 1351-1357. (Pubitemid 32378389)
7. Carson, P., Ziesche, S., Johnson, G. and Cohn, J. N. (1999), 'Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials', J. Card. Fail., Vol. 5, pp. 178-187. (Pubitemid 29449255)
8. Kohno, M, Yokokawa, K., Minami, M. et al. (1999), 'Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors', Am. J. Med., Vol. 106, pp. 544-549. (Pubitemid 29231105)
9. Rigat, B., Hubert, C, Alhenc-Gelas, F., Cambien, F., Corvol, P. and Soubrier, F. (1990), 'An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels', J. Clin. Invest., Vol. 86, pp. 1343-1346. (Pubitemid 20370444)
10. Sasaki, M., Oki, T., Iuchi, A. et al. (1996), 'Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension'. M- mode and pulsed Doppler echocardiographic studies', J. Hypertens., Vol. 14, pp. 1403-1408.
11. Ohmichi, N., Iwai, N., Uchida, Y., Shichiri, G., Nakamura, Y. and Kinoshita, M (1997), 'Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype', Am. J. Hypertens., Vol. 10, pp. 951-955,
12. Danser, A. H. and Schunkert, H. (2000), 'Renin-angiotensin system gene polymorphisms: potential mechanisms for their association with cardiovascular diseases', Eur. J. Pharmacol, Vol. 410, pp. 303-316. (Pubitemid 32008152)
13. Mizuiri, S., Yoshikawa, H., Tanegashima, M. et al. (1998),'Renal ACE immunohistochemical localization in NIDDM patients with nephropathy', Am. J. Kidney Dis., Vol. 31, pp. 301-307. (Pubitemid 28106422)
14. Dieguez-Lucena, J. L., Aranda-Lara, P., Ruiz-Galdon, M., Garcia-Villanova, J., Morell-Ocana, M. and Reyes-Engel, A. (1996), 'Angiotensin I-converting enzyme genotypes and angiotensin II receptors. Response to therapy', Hypertension, Vol. 28, pp. 98-103. (Pubitemid 26231096)
15. Stavroulakis, G. A., Makris, T. K., Krespi, P. G. et al. (2000), 'Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism', Cardiovasc. Drugs. Ther., Vol. 14, pp. 427-432. (Pubitemid 30663725)
16. Ueda, S., Meredith, P. A., Morton. J.J., Connell, J. M. and Elliott, H. L. (1998), 'ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans', Circulation, Vol. 98, pp. 2148-2153. (Pubitemid 28527474)
17. Pinto, Y. M., van Gilst, W. H., Kingma, J. H. and Schunkert, H. (1995), 'Deletion-type allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilation after anterior myocardial infarction', J. Am. Coll. Cardiol., Vol. 25, pp. 1622-1626.
18. Sasaki, M, Oki, T., Iuchi, A. et al. (1996), 'Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies', J. Hypertens., Vol. 14, pp. 1403-1408.
19. Prasad, A., Narayanan, S., Husain, S. et al. (2000), 'Insertion-deletion polymorphism of the ACE gene modulates reversibility of endothelial dysfunction with ACE inhibition', Circulation, Vol. 102, pp. 35-41. (Pubitemid 30430550)
20. Jeunemaitre, X., Soubrier, F., Kotelevtsev, Y. V. et al. (1992), 'Molecular basis of human hypertension: role of angiotensinogen', Cell, Vol. 71, pp. 169-180.
21. Schunkert, H., Hense, H. W., Gimenez-Roqueplo, A. P. et al. (1997), 'The angiotensinogen T235 variant and the use of antihypertensive drugs in a population-based cohort', Hypertension, Vol. 29, pp. 628-633. (Pubitemid 27074729)
22. Hingorani, A. D., Jia, H., Stevens, P. A., Hopper, R., Dickerson, J. E. and Brown, M.J. (1995), 'Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition', J. Hypertens., Vol. 13, pp. 1602-1609. (Pubitemid 26015783)
23. Benetos, A., Cambien, F., Gautier, S. et al. (1996), 'Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of Perindopril and nitrendipine on arterial stiffness in hypertensive individuals'. Hypertension, Vol. 28, pp. 1081-1084. (Pubitemid 26415828)
24. Miller, J. A., Thai, K. and Scholey, J. W. (1999), 'Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II', Kidney Int., Vol. 56, pp. 2173-2180. (Pubitemid 30004746)
25. Lithell, H., Berglund, L., Jonsson, J., Heutchel, K. and Jonsson, L. (1999), 'Prediction ofblood pressure-response to ACE inhibitors by using patterns of genetic variation in the RAAS', Circulation, Vol. 100, p. 1755.
26. Mukae, S., Aoki, S., Itoh, S., Iwata, T., Ueda, H. and Katagiri, T. (2000), 'Bradykinin B(2) receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor-related cough', Hypertension, Vol. 36, pp. 127-131. (Pubitemid 30602164)
27. Takahashi, T., Yamaguchi, E., Furuya, K. and Kawakami, Y. (2001), 'The ACE gene polymorphism and cough threshold for capsaicin after Cilazapril usage', Respir. Med., Vol. 95, pp. 130-135. (Pubitemid 32624444)
28. Maqbool, A., Hall, A. S., Ball, S. G. and Balmforth, A.J. (1999), 'Common polymorphisms of beta 1-adrenoceptor: identification and rapid screening assay', Lancet, Vol. 353, p. 897. (Pubitemid 29126881)
29. Drysdale, C. M., McGraw, D. W., Stack, C. B. et al. (2000), 'Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness', Proc. Natl. Acad. Sci. USA, Vol. 97, pp. 10483-10488.
30. Xie, H. G., Dishy, V., Sofowora, G. et al. (2001), 'Arg389Gly beta 1-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo', Pharmacogenetics, Vol. 11, pp. 191-197. (Pubitemid 32319868)
31. Mason, D. A., Moore, J. D., Green, S. A. and Liggett, S. B. (1999), 'A gain-of-function polymorphism in a G-protein coupling domain of the human betal-adrenergic receptor', J. Biol. Chem., Vol. 274, pp. 12670-12674.
32. Bengtsson, K., Melander, O., Orho-Melander, M. et al. (2001), 'Polymorphism in the (beta) 1-adrenergic receptor gene and hypertension', Circulation, Vol. 104, pp. 187-190. (Pubitemid 32655836)
33. Humma, L. M., Puckett, B. J., Richardson, H. E. et al. (2001), 'Effects of beta 1-adrenoceptor genetic polymorphisms on resting hemodynamics in patients undergoing diagnostic testing for ischemia', Am. J. Cardiol, Vol. 88, pp. 1034-1038.
34. Li, G. H., Faulhaber, H. D., Rosenthal, M. et al. (2001), 'Beta-2 adrenergic receptor gene variations and blood pressure under stress in normal twins', Psychophysiology, Vol. 38, pp. 485-489. (Pubitemid 32422292)
35. Busjahn, A., Li, G. H., Faulhaber, H. D. et al (2000), 'Beta-2 adrenergic receptor gene variations, blood pressure, and heart size in normal twins', Hypertension, Vol. 35, pp. 555-560. (Pubitemid 30108148)
36. Timmermann, B., Mo, R., Luft, F. C. et al. (1998), 'Beta-2 adrenoceptor genetic variation is associated with genetic predisposition to essential hypertension: the Bergen Blood Pressure Study', Kidney Int., Vol. 53, pp. 1455-1460. (Pubitemid 28243726)
37. Bray, M. S., Krushkal, J., Li, L. et al. (2000), 'Positional genomic analysis identifies the beta(2)-adrenergic receptor gene as a susceptibility locus for human hypertension', Circulation, Vol. 101, pp. 2877-2882. (Pubitemid 30415875)
38. Gratze, G., Fortin, J., Labugger, R. et al. (1999), 'Beta-2 adrenergic receptor variants affect resting blood pressure and agonist-induced vasodilation in young adult Caucasians', Hypertension, Vol. 33, pp. 1425-1430. (Pubitemid 29282665)
39. Hoit, B. D., Suresh, D. P., Craft, L., Walsh, R. A. and Liggett, S. B. (2000), 'Beta 2-adrenergic receptor polymorphisms at amino acid 16 differentially influence agonist-stimulated blood pressure and peripheral blood flow in normal individuals', Am. Heart J., Vol. 139, pp. 537-542. (Pubitemid 30149205)
40. Cockcroft, J. R., Gazis, A. G., Cross, D.J. et al. (2000), 'Beta(2)-adrenoceptor polymorphism determines vascular reactivity in humans'. Hypertension, Vol. 36, pp. 371-375.
41. Borjesson, M., Magnusson, Y., Hjalmarson, A. and Andersson, B. (2000), 'A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure', Eur. Heart J., Vol. 21, pp. 1853-1858.
42. McNamara, D. M., Holubkov, R., Janosko, K. et al. (2001), 'Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure', Circulation, Vol. 103, pp. 1644-1648. (Pubitemid 32246611)
43. O'Shaughnessy, K. M., Fu, B., Dickerson, C, Thurston, D. and Brown, M.J. (2000), 'The gain-of-function G389R variant of the beta 1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects', Clin. Sci. (Colch.), Vol. 99, pp. 233-238.
44. Jia, H., Hingorani, A. D., Sharma, P. et al. (1999), 'Association of the G(s)alpha gene with essential hypertension and response to beta-blockade', Hypertension, Vol. 34, pp. 8-14. (Pubitemid 29325711)
45. Turner, S. T., Schwartz, G. L., Chapman, A. B. and Boerwinkle, E. (2001), 'C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic', Hypertension, Vol. 37, pp. 739-743. (Pubitemid 32199059)
46. Glorioso, N., Manunta, P., Filigheddu, F. et al. (1999), 'The role of alpha-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study', Hypertension, Vol. 34, pp. 649-654. (Pubitemid 29496448)
47. Cusi, D., Barlassina, C, Azzani, T. et al. (1997), 'Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension', Lancet, Vol. 349, pp. 1353-1357. (Pubitemid 27197537)
48. Gerdes, L. U., Gerdes, C, Kervinen, K. et al. (2000), 'The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study', Circulation, Vol. 101, pp. 1366-1371. (Pubitemid 30169856)
49. Nemeth, A., Szakmary, K., Kramer, J. et al. (1995), 'Apolipoprotein E and complement C3 polymorphism and their role in the response to gemfibrozil and low fat low cholesterol therapy', Eur. J. Clin. Client. Clin. Biochcm., Vol. 33, pp. 799-804.
50. Ordovas, J. M., Lopez-Miranda, J., Perez-Jimenez, F. et al. (1995), 'Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy', Atherosclerosis, Vol. 113, pp. 157-166.
51. Kuivenhoven, J. A., Jukema, J. W., Zwinderman, A. H. et al. (1998), 'The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis', N. Engl. J. Med., Vol. 338, pp. 86-93. (Pubitemid 28042271)
52. de Maat, M. P., Jukema, J. W., Ye, S. et al. (1999), 'Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis', Am. J. Cardiol., Vol. 83, pp. 852-856. (Pubitemid 29143120)
53. de Maat, M. P., Kastelein, J. J., Jukema, J. W. et al. (1998), '-455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen', Arterioscler. Thromb. Vasc. Biol., Vol. 18, pp. 265-271. (Pubitemid 28277604)
54. Humphries, S. E., Luong, L. A., Talmud, P.J. et al. (1998), 'The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study', Atherosclerosis, Vol. 139, pp. 49-56. (Pubitemid 28341866)
55. Heath, K. E., Gudnason, V., Humphries, S. E. and Seed, M. (1999), 'The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia', Atherosclerosis, Vol. 143, pp. 41-54. (Pubitemid 29138702)
56. Jukema, J. W., van Boven, A. J., Groenemeijer, B. et al. (1996), 'The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis', Circulation, Vol. 94, pp. 1913-1918. (Pubitemid 26349305)
57. Marian, A. J., Safavi, F., Ferlic, L., Dunn, J. K., Gotto, A. M. and Ballantyne, C. M. (2000), 'Interactions between angiotensin-I Converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study', J. Am. Coll. Cardiol, Vol. 35, pp. 89-95. (Pubitemid 30061265)
58. Salazar, L. A., Hirata, M. H., Quintao, E. C. and Hirata, R. D. (2000), 'Lipid-lowering response of the HMG-CoA reductase inhibitor fluvastatin is influenced by polymorphisms in the low-density lipoprotein receptor gene in Brazilian patients with primary hypercholesterolemia', J. Clin. Lab. Anal., Vol. 14, pp. 125-131. (Pubitemid 30250114)
59. Martinelli, I., Sacchi, E., Landi, G., Taioli, E., Duca, F. and Mannucci, P. M. (1998), 'High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives', N. Engl. J. Med., Vol. 338, pp. 1793-1797. (Pubitemid 28277959)
60. Martinelli, I., Taioli, E., Bucciarelli, P., Akhavan, S. and Mannucci, P. M. (1999), 'Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis', Arterioscler. Thromb. Vasc. Biol., Vol. 19, pp. 700-703. (Pubitemid 29135174)
61. Brandt, J. T., Isenhart, C. E., Osborne, J. M., Ahmed, A. and Anderson, C. L. (1995), 'On the role of platelet Fc gamma Rlla phenotype in heparin-induced thrombocytopenia', Thromb. Haemost., Vol. 74, pp. 1564-1572.
62. Michelson, A. D., Furman, M. I., Goldschmidt-Clermont, P. et al. (2000), 'Platelet GP IIIa P1(A) polymorphisms display different sensitivities to agonists', Circulation, Vol. 101, pp. 1013-1018. (Pubitemid 30131704)
63. Cooke, G. E., Bray, P. F., Hamlington, J. D., Pham, D. M. and Goldschmidt-Clermont, P.J. (1998), 'P1A2 polymorphism and efficacy of aspirin', Lancet, Vol. 351, p. 1253.
64. Szczeklik, A., Sanak, M. and Undas, A. (2001), 'Platelet glycoprotein IIIa pl(a) polymorphism and effects of aspirin on thrombin generation', Circulation, Vol. 103, pp. E33-34.
65. Szczeklik, A., Undas, A., Sanak, M., Frolow, M. and Wegrzyn, W. (2000), 'Relationship between bleeding time, aspirin and the P1A1/ A2 polymorphism of platelet glycoprotein IIIa', Br. J. Haematol., Vol. 110, pp. 965-967.
66. Boudoulas, K.D., Cooke, G. E., Roos, C. M., Bray, P. F. and Goldschmidt-Clermont, P. J. (2001), 'The P1A polymorphism of glycoprotein IIIa functions as a modifier for the effect of estrogen on platelet aggregation', Arch. Pathol. Lab. Med., Vol. 125, pp. 112-115. (Pubitemid 32096194)
67. Napolitano, C, Schwartz, P. J., Brown, A. M. et al. (2000), 'Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias', J. Cardiovasc. Electrophysiol., Vol. 11, pp. 691-696. (Pubitemid 30397542)
68. Drici, M. D. and Barhanin, J. (2000), 'Cardiac K+ channels and drug-acquired long QT syndrome', Therapie, Vol. 55, pp. 185-193. (Pubitemid 30319280)
69. Abbott, G. W., Sesti, F., Splawski, I. et al. (1999), 'MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia', Cell, Vol. 97, pp. 175-187.
70. Escande, D. (2000), 'Pharmacogenetics of cardiac K(+) channels', Eur. J. Pharmacol., Vol 410, pp. 281-287.
71. Roden, D. M. (2001), 'Pharmacogenetics and drug-induced arrhythmias', Cardiovasc. Res., Vol. 50, pp. 224-231. (Pubitemid 32382149)
72. Lithell, H., Berglund, L., Jonsson, J. and Jonsson, L. (1999), 'Prediction of blood pressure response to ACE inhibitors by using patterns of genetic variation in the RAAS', Circulation, Vol. 100, pp. 1755.
73. Arranz, M. J., Munro, J., Birkett, J. et al. (2000), 'Pharmacogenetic prediction of clozapine response', Lancet, Vol. 355, pp. 1615-1616. (Pubitemid 30240510)
74. Nakajima, M., Kwon, J. T., Tanaka, N. et al (2001), 'Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans', Clin. Pharmacol. Ther., Vol. 69, pp. 72-78. (Pubitemid 32108674)
75. Oscarson, M., McLellan, R. A., Gullsten, H. et al. (1999), 'Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism', FEBS Lett., Vol. 460, pp. 321-327. (Pubitemid 29495962)
76. Pianezza, M. L., Sellers, E. M. and Tyndale, R. F. (1998), 'Nicotine metabolism defect reduces smoking', Nature, Vol. 393, p. 750. (Pubitemid 28299478)
77. Ockene, I. S. and Miller, N. H. (1997), 'Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association', Circulation, Vol. 96, pp. 3243-3247. (Pubitemid 27500133)
78. Stubbins, M. J., Harries, L. W., Smith, G., Tarbit, M. H. and Wolf, C. R. (1996), 'Genetic analysis of the human cytochrome P450 CYP2C9 locus', Pharmacogenetics, Vol. 6, pp. 429-439. (Pubitemid 26380099)
79. Hirsh J., Dalen, J., Anderson, D. R. et al. (2001), 'Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range', Chest, Vol. 119(1 Suppl), pp. 8S-21S. (Pubitemid 32154192)
80. Taube, J., Halsall, D. and Baglin, T. (2000), 'Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment', Blood, Vol. 96, pp. 1816-1819. (Pubitemid 30661066)
81. Freeman, B. D., Zehnbauer, B. A., McGrath, S., Borecki, I. and Buchman, T. G. (2000), 'Cytochrome P450 polymorphisms are associated with reduced warfarin dose', Surgery, Vol. 128, pp. 281-285. (Pubitemid 30623510)
82. Halkin, H. and Lubetsky, A. (1999), 'Warfarin dose requirement and CYP2C9 polymorphisms', Lancet, Vol. 353, pp. 1972-1973. (Pubitemid 29255727)
83. Aithal, G. P., Day, C. P., Kesteven, P.J. and Daly, A. K. (1999), 'Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications', Lancet, Vol. 353, pp. 717-719. (Pubitemid 29103806)
84. Marez, D., Legrand, M., Sabbagh, N. et al. (1997), 'Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution', Pharmacogenetics, Vol. 7, pp. 193-202. (Pubitemid 27290633)
85. Lennard, M. S., Silas, J. H., Freestone, S., Ramsay, L. E., Tucker, G. T. and Woods, H. F. (1982), 'Oxidation phenotype - a major determinant of metoprolol metabolism and response', N. Engl. J. Med., Vol. 307, pp. 1558-1560. (Pubitemid 13245431)
86. Lennard, M. S., Tucker, G. T., Silas, J. H., Freestone, S., Ramsay, L. E. and Woods, H. F. (1983), 'Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers', Clin. Pharmacol. Ther., Vol. 34, pp. 732-737. (Pubitemid 14219918)
87. Silas, J. H., Lennard, M. S., Tucker, G. T., Ramsay, L. E. and Woods, H. F. (1984), 'Polymorphic metabolism of beta-adrenoceptor antagonists', Br. J. Clin. Pharmacol., Vol. 17(Suppl 1), pp. 11S-19S.
88. Labbe, L., O'Hara, G., Lefebvre, M. et al. (2000), 'Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings', Clin. Pharmacol. Ther., Vol. 68, pp. 44-57. (Pubitemid 30609826)
89. Johnson, J. A. and Burlew, B. S. (1996), 'Metoprolol metabolism via cytochrome P4502D6 in ethnic populations', Drug Metab. Dispos., Vol. 24, pp. 350-355. (Pubitemid 26087089)
90. Rebbeck, T. R., Jaffe, J. M., Walker, A. H., Wein, A.J. and Malkowicz, S. B. (1998), 'Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4', J. Natl. Cancer Inst., Vol. 90, pp. 1225-1229. (Pubitemid 28407089)
91. Ball, S. E., Scatina, J., Kao, J. et al. (1999), 'Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4', Clin. Pharmacol. Ther., Vol. 66, pp. 288-294. (Pubitemid 29451761)
92. Fretland, A. J., Leff, M. A., Doll, M. A. and Hein, D. W. (2001), 'Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms', Pharmacogenetics, Vol. 11, pp. 207-215. (Pubitemid 32319870)
93. Weber, W. W. and Hein, D. W. (1985), 'N-acetylation pharmacogenetics', Pharmacol. Rev., Vol. 37, pp. 25-79. (Pubitemid 15081093)
94. Mansilla-Tinoco, R., Harland, S. J., Ryan, P.J. et al. (1982), 'Hydralazine, antinuclear antibodies, and the lupus syndrome', Br. Med. J., Vol. 284, pp. 936-939. (Pubitemid 12192944)
95. Woosley, R. L., Drayer, D. E., Reidenberg, M. M., Nies, A. S, Carr, K. and Oates, J. A. (1978), 'Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome', N. Engl. J. Med., Vol. 298, pp. 1157-1159. (Pubitemid 8356479)
96. Hoffmeyer, S., Burk, O., von Richter, O. et al. (2000), 'Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo', Proc. Natl. Acad. Sci. USA, Vol. 97, pp. 3473-3478. (Pubitemid 30183327)
97. Ameyaw, M. M., Regateiro, F., Li, T. et al. (2001), 'MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity'. Pharmacogenetics, Vol. 11, pp. 217-221. (Pubitemid 32319871)